Enter your search term below:
ISCT–JSRM 5-Year Joint Strategic Collaboration on Clinical iPSCs Launches Inaugural Joint Collaboration in Kobe, Japan - March 21, 2026 VANCOUVER, CANADA and TOKYO, JAPAN – 3 March 2026 -- The International Society for Cell & Gene...
The ISCT Major Awards are the highest honor bestowed by the Society to recognize the outstanding achievements and extraordinary contributions of individuals to the field of cell and gene therapy globally. Learn more about our award categories below and submit your nomination(s) by February 16...
The International Society for Cell & Gene Therapy (ISCT), Alliance for Regenerative Medicine (ARM), and American Society of Gene & Cell Therapy (ASGCT) reaffirm our collective position, as articulated in the Cytotherapy editorial “ International Call for a 10-Year Moratorium on...
Applications are now open for the 8th Annual ISCT Early Stage Professionals (ESP) Mentoring Program ! Celebrating nearly a decade of impact, this global initiative has connected hundreds of professionals in the cell and gene therapy (CGT) field — advancing careers, sparking meaningful...
The ISCT Nominations Committee is Seeking Candidates for Global and Regional Leadership Positions ISCT strives to identify members who are committed to lead our organization into the future. The Board of Directors and Regional Executive Committee members work diligently to implement...
The International Society for Cell & Gene Therapy (ISCT), in partnership with the Alliance for Regenerative Medicine (ARM) and the American Society of Gene & Cell Therapy (ASGCT), today issued a unified joint statement calling for a 10-year global moratorium on heritable human genome...
January 29, 2025 – The International Society for Cell & Gene Therapy (ISCT) is delighted to announce the appointment of Phil Vanek, PhD, as the new ISCT Chief Commercialization Officer (CCO), effective January 1, 2025, through December 31, 2026. Dr. Vanek is an internationally...
VANCOUVER, British Columbia, December 20, 2024 - The International Society for Cell & Gene Therapy (ISCT) celebrates the US Food and Drug Administration’s (FDA) landmark decision to approve Mesoblast Limited’s allogenic, bone marrow-derived mesenchymal stromal cell (MSC) product,...
October 3 rd , 2024 – The International Society for Cell & Gene Therapy (ISCT) celebrates a major legal victory in the ongoing fight to protect the public from unregulated cell and gene therapies. In U.S. v. California Stem Cell Treatment Center, Inc., the U.S. Court of Appeals for...
The International Society for Cell & Gene Therapy (ISCT) celebrates the recent announcement of the U.S. Food and Drug Administration's (FDA) accelerated approval of Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have...